Prior to Artios, Helen was at MISSION Therapeutics where she was both a team and project leader responsible for various drug discovery efforts up to the preclinical stage, leading both …

At Artios, we converge decades of experience from unparalleled DDR insights encapsulating multiple pathways to create breakthrough cancer medicines.

Artios is advancing an industry-leading pipeline of therapeutic candidates that target a broad range of solid tumors.

2021年6月17日 · CAMBRIDGE, UK and NEW YORK, USA, 17 June 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based …

2023年2月9日 · CAMBRIDGE, UK and NEW YORK, USA, 9 February 2023: Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small …

2022年8月10日 · Artios is building a pipeline of next-generation DDR programs to target hard to treat cancers, including its ATR inhibitor, ART0380, and the Polθ inhibitor, ART4215, as a …

2021年4月7日 · Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in …

2024年12月19日 · CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage …

2020年12月3日 · Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. It is backed by blue chip investors including: AbbVie Ventures, Andera …

There is no excerpt because this is a protected post.